Skip to main content
  1. Right Decisions
  2. Maternity & Gynaecology Guidelines
  3. Maternity
  4. Back
  5. Common obstetric problems, intrapartum labour ward
  6. Induction of Labour (562)
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Induction of Labour (562)

Warning

Objectives

Induction of labour for Primigravida and Parous Women (excluding those with previous CS)

Please report any inaccuracies or issues with this guideline using our online form

The process of induction should only be considered when vaginal delivery is felt to be an option for delivery.  A Consultant Obstetrician should be involved in the decision making in induction of all high risk pregnancies. 

Some inductions are triggered by clinical events such as decreased fetal movements, PPROM, SROM> 36 + 6 WEEKS. See relevant guidelines.

Uncomplicated pregnancies should be offered induction of labour between 41+ 0 and 42 + 0 weeks (i.e. T+7 and T+14).

A membrane sweep should be offered – see separate guideline.

From 42 weeks, women who decline induction of labour should be offered increased antenatal monitoring consisting of at least twice – weekly cardiotocography and ultrasound estimation of maximum amniotic pool depth.   

Maternal request:

Induction of labour should not routinely be offered on maternal request alone. However, under exceptional circumstances (for example, if the woman’s partner is soon to be posted abroad with the armed forces), induction may be considered at or after 40 weeks. 

When planning induction of labour think about indication and aim for weekday delivery for Diabetics, BMI ≥ 40, Twins, severe underlying medical conditions, High anaesthetic risk, VBAC (ARM only) or any VBAC with Consultant sanctioned use of PG. If weekend delivery unavoidable ensure all relevant staff aware of patient. 

Method of IOL

Primigravida  and Parous Women (excluding those withprevious CS)

  • Review Case Notes and establish plan
  • Confirm cephalic presentation and FH activity. If in doubt ultrasound by trained medical staff.
  • Prostaglandins should be used in preference to ARM and Syntocinon in both prims & parous women with intact membranes, regardless of their cervical favourability.
  • Dinoprostone (Prostin ®) 3mgs vaginal tablets is the induction agent of choice
  • If the cervix is favourable for an ARM after a single dose of Prostin ® an ARM should be performed, otherwise a further dose of Prostin ® should be given. Appropriately trained midwives can administer these.

Women who are not suitable for amniotomy after 2 doses of dinoprostone.

  1. Remember to check patient has not had previous treatment to her cervix (e.g. cold coagulation). Occasionally insertion of a digit through the cervix is required to break down adhesions caused by such treatment.

  2. A further 3mg of prostin - note that this is outwith the Manufacturer's recommendations but acceptable in GGC on basis of peer practice/consensus. This may be administered by a suitably trained midwife.
    Note  Amniotomy is usually possible if the cervix admits a finger. Examining a patient on a Labour Ward couch, with or without lithotomy position may facilitate this.

  3. Mechanical induction with a Foley's balloon catheter. Technique - a 12 Fg Foley's balloon is inserted aseptically through the cervical os and the balloon inflated with 10ml sterile sodium chloride 0.9% for inj.  and 30ml sterile sodium chloride 0.9% for inj. injected through the lumen into the extra amniotic space. The inflated balloon should be left in situ until the next day, or until the balloon falls out.

  4. If amniotomy is not possible then the patient should be discussed with a senior Obstetrician (Consultant or ST7) and depending on the reason for IOL, offered:
    a) 24 hours “rest” and then re-start prostaglandin.
    b) Caesarean Section
  • Amniotomy should be performed prior to commencement of Syntocinon infusion.

  • Oxytocin (Syntocinon ®) should not be started within 6 hours following administration of vaginal Prostaglandins.

Fetal surveillance and IOL

  • CTG facilities must be available.
  • Fetal wellbeing should be established immediately prior to administration of vaginal Prostaglandins by means of continuous CTG for 20 minutes.
  • Induction with Prostaglandins should only proceed if CTG is reassuring.
  • Fetal wellbeing should be observed by continuous CTG for 30 minutes following the insertion of vaginal Prostaglandins.
  • Following IOL with vaginal Prostaglandins, fetal wellbeing should be established once contractions are detected or reported or SROM occurs. This should be by initial CTG assessment and then intermittent monitoring in uncomplicated pregnancies. High risk pregnancies should have continuous CTG monitoring once regular uterine activity 
  • Where Oxytocin (Syntocinon ®) is used for induction or augmentation, continuous CTG monitoring should be used in all cases.

Women who decline IOL

Offer of induction declined from 42 weeks.

  • Initiate serial monitoring at 42 weeks in Day Care Unit
  • Measurement of single deepest pool of liquor and umbilical artery doppler
  • Twice weekly CTG
  • Senior Obstetric review

The above monitoring plan is “prognostic.” There is no evidence that monitoring can predict stillbirth in past date pregnancy and the patient must be informed about this. 

Advise delivery if monitoring abnormal.

Admissions procedure

  • All women should be admitted to the priming area on the day of Dinoprostone (Prostin ®) administration.
  • Checklist should be completed appropriately by the midwife in the low risk cases.
  • Confirm cephalic presentation. If in doubt – ultrasound by trained medical staff.
  • In high risk inductions the Middle Grade Obstetrician and Anaesthetist should be made aware of the relevant risks.
  • Anaesthetist should be alerted when high risk maternal conditions present. (See relevant list).
  • FBC should be taken if no sample within previous 4 weeks or if platelets <200.
  • Check Group B Strep status and have antibiotics prescribed if appropriate. (These should commence as soon as patient is in labour)
  • Healthy women with uncomplicated pregnancies should have vaginal Prostaglandins administered in the priming area. The ward staff should liaise with Labour Suite (LS) / Middle Grade Obstetrician regarding workload.
  • Women with recognised risk factors should be induced in an area appropriate to the particular risk after discussion with a Senior Obstetrician.
    i.e.
    • Previous CS
    • Recent APH
    • High parity ≥4
    • Any patient requiring a continuous CTG
    • AC <10th centile
    • Severe pre-eclampsia
    • SRM meconium not in labour
    • Twins
    • Severe asthma (previous hospitalisation or on oral steroids)
    • Oligohydramnios (deepest pool of liquor < 2cm)
    • Anaesthetic high risk patients
    • Any patients identified as high risk by a Consultant Obstetrician

Inductions on Antenatal Ward

  • Meals may be given as normal if CTG reassuring and not contracting regularly.
  • Appropriate analgesia should be offered.
  • Aim for transfer to LS by 8am the following morning for ARM.
  • Transfer to LS earlier if any concern regarding CTG or if labour becomes established (confirmed by cervical assessment).

Appendix on the Management of IOL Following Previous Caesarean Section (See VBAC policy)

Induction by any means is associated with an increased risk of uterine rupture. This risk is highest with PG induction.

Contraindications:

  • Uterine scar of unknown type or upper segment scar
  • Placenta praevia
  • Fetal malpresentation
  • History of uterine rupture
  • Absolute cephalopelvic disproportion

Requirements

  • Clinical discussion regarding the timing and method of IOL must take place at Consultant level after cervical assessment
  • A clear management plan including method of induction should be made and documented in the casenotes.
  • This management plan should take into account cervical findings
  • IOL in the presence of an unfavourable cervix requires careful consideration – appropriate alternatives may include elective Caesarean section or later review in anticipation of spontaneous labour or cervical ripening
  • The Middle Grade Obstetrician on-call should be aware of the patient’s presence on the labour ward
  • A venflon should be in place and blood sent for FBC and G&S IF Consultant has sanctioned use of vaginal PG,  Vaginal Prostaglandins (Prostin tablets 3mgs) should be administered at 10pm and the cervix reassessed by the Registrar at 6am.  One further dose of Prostin (3mgs) could then be given, but careful consideration of the clinical situation is essential
  • Difficult ARM is to be avoided
  • Syntocinon may be initiated following ARM, but should not be started within 6 hours of Prostin, as this may lead to uterine hypertonus. (Syntocinon should be prescribed by the Registrar on-call).
  • The use of Syntocinon should always be cautious (refer to Syntocinon and VBAC guidelines)
  • CTG should be commenced 20 minutes prior to assessment and continue for at least 30 minutes afterwards. Continuous EFM is indicated from the onset of uterine activity following ARM and during administration of IV Syntocinon
  • Adequate progress in labour should be confirmed by VE at least 4 hourly/or as indicated and advice sought if there is deviation from expected progress
  • The decision to deliver by emergency CS should be made at Consultant level
  • The casenotes should contain full and accurate documentation of events
  • This is a GUIDELINE – flexibility in individual cases is inevitable, but management decisions should occur at senior level where possible and be clearly documented.

Pre-labour ROM at Term (>37 weeks gestation) FollowingPrevious CS:

If trial of vaginal delivery has been agreed:

  • Exclude malpresentation
  • Offer options as usual in pre-labour SROM, i.e Immediate IOL or IOL after 24 hours, in which case patient should remain as in-patient
  • Perform baseline VE prior to IOL
  • IOL method of choice is IV Syntocinon

MULTIGRAVIDA (no previous CS) – Low and high risk (flowchart)

Maximum 3mg Prostin each dose  (three doses total) in all cases (see text).

PRIMIGRAVIDA - Low and high risk (flowchart)

Maximum 3mg Prostin each dose  (three doses total) in all cases

Editorial Information

Last reviewed: 29/08/2017

Next review date: 31/07/2023

Author(s): Katie McBride.

Version: 2

Approved By: Obstetrics Clinical Governance Group

Document Id: 562